![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CRUCELL AND DSM ANNOUNCE PER.C6 LICENSING AGREEMENT
CRUCELL AND DSM ANNOUNCE PER.C6 LICENSING AGREEMENT
July 18, 2005
Dutch biotechnology company Crucell and allied contract manufacturer DSM Biologics have signed a PER.C6 research license agreement with Danish biotechnology company Symphogen.
The license agreement allows Symphogen to evaluate and use the PER.C6 cell line for production of its proprietary recombinant polyclonal antibodies, known as symphobodies.
Symphogen has opted to evaluate the PER.C6 cell line for use with Sympress, its proprietary expression platform, for consistent manufacturing of its symphobody compositions.
Under the terms of the agreement, Symphogen will pay a signing fee and annual maintenance fees. Further financial details are not disclosed.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct